Open in interactive viewer → charts, metric popovers & call review

Amaero Got Its Nasdaq Listing. Now It Has to Absorb Its Own Factory

A $13.4M firm backlog, 35% growth and a formal Q4 guide — delivered alongside a $4.4M gross loss as titanium capacity sat under-utilized
3DA.AX · Earnings Call · 2026-11-09

The listing did more work than any single line item

Amaero's inaugural Nasdaq call is also its first reported in US dollars under US GAAP, and the reframing deserves more attention than it got. In April, management “reaffirmed $18 million to $20 million guidance” — Hank Holland, Chairman and CEO · 2026-04-21 for the fiscal year ending June. That number appears nowhere in today's materials. Instead we get a calendar-2026 framework: $16.0–16.5 million, up 154%–162%, with Q4 guided to $4.5–5.0 million. The bridge is real — the June year actually produced $12.5 million, which is roughly the old Australian-dollar range translated — but the currency and fiscal-year conversion quietly retired a guidance framework that had been reaffirmed twice. No analyst asked about it. What the new wrapper does deliver is a firmer contract: a formal Q4 range, a cost structure management calls largely sunk, and a backlog of $13.44 million — backlog up 180% year-over-year and roughly equal to trailing-twelve-month revenue of $13.5 million. Thematically, the chairman's framing is unchanged from prior calls: rebuilding the US defense industrial base, reshoring, and additive manufacturing, with Department of War money and a first low-rate production contract now attached to it. That theme is not company-unique anymore — defense-industrial reporters across this window (Kratos, Loar, Ducommun, Mercury, Rheinmetall) are all narrating the same funding cycle.

The quarter that growth built and cost accounting ate

Revenue rose 35% to $4.11 million, near the top of the pre-announced range. Metal powders contributed $3.2 million (+19%); PM HIP contributed $0.9 million, up 146%, including the first revenue from the BPMI contract. Then the other line: cost of revenue of $8.5 million against $4.11 million of sales, producing a $4.4 million gross loss, a net loss of $9.06 million ($0.38 per share), and adjusted EBITDA of negative $7.1 million. Management's explanation is specific and, notably, self-inflicted by success of a sort. Titanium production restarted in late July after the six-week safety pause — a dust-hazard review with Jensen Hughes that has since vanished from the conversation entirely — and then the new sieving system was commissioned in August. Hank Holland was blunt: “the sieving is the bottleneck process of powder production” — Hank Holland, Chairman and Chief Executive Officer · 2026-11-09, and “the yield was below optimal for last quarter” — Hank Holland, Chairman and Chief Executive Officer · 2026-11-09. Unabsorbed production labor plus poor yields turned a growth quarter into a negative gross margin. The bull argument is that this is a fixed-cost story. Brett Paduch: “the fixed cost in our cost of goods sold is significantly scaled at this point” — Brett Paduch, Chief Financial Officer · 2026-11-09. Fair — but Holland immediately dampened it, flagging a six-week inventory lag and conceding “we really will not begin to see the favorable trend as we would expect until we get into the next calendar year” — Hank Holland, Chairman and Chief Executive Officer · 2026-11-09. So Q4 gets the revenue, not the margin. Here is the tension that matters most. Six months ago the titanium story was scarcity:

This current quarter, on the atomizer dedicated titanium, we are adding 100% capacity utilization. We're full. We cannot accept other orders this quarter.

Hank Holland, Chairman and CEO · 2026-04-21
Today, titanium ran below installed capacity. And the company still intends to commission its fourth atomizer in June 2027, lifting capacity from roughly 680 metric tons to 920 — adding supply into a line that just demonstrated it cannot yet fill what it has. That is the pivot from build-out to execution, and it is less comfortable than the press release implies.

Firm backlog, fragile calendar

The best answer of the call came on backlog quality. Under a continuing resolution, Holland was categorical: “All of the backlog as reported is contracted firm orders” — Hank Holland, Chairman and Chief Executive Officer · 2026-11-09, with only about $700,000 of Department of War payments outstanding and everything expected to be recognized before June 30. He also wryly noted that the BPMI award — the seventh contract with that counterparty, but the first production contract at roughly $350,000 — signals a coming series of contract with BPMI follow-ons that sit in pipeline, not backlog. But the recurring risk is now a pattern, not an event. In April, Hank blamed delayed contracting on “the FY '25 continuing resolution and the government shutdown” — Hank Holland, Chairman and CEO · 2026-04-21. Six months later, the same CR mechanism is back for FY2027, and the answer is a shrug about midterms and February budget passage. Twice in a row, the US appropriations calendar has either delayed revenue or clouded visibility for a company with a $150 million market cap. That is a structural feature of the customer, not a one-off.

Hafnium is the tell

The most under-discussed item: Amaero's flagship refractory alloy, niobium C103, contains about 10% hafnium, and Hafnium pricing has gone vertical — up ~75% in nine months as of April, described in November as up about 700% over several years. The company's $4.5 million DoW award exists precisely to develop hafnium-free alternatives. Read that again: Amaero's largest single contract is partly a hedge against the input cost of its own best-known product, and a bet that C103's six-decade qualification moat gets partially designed around. It also means the high-value refractory line, one atomizer's worth, is where pricing power and substitution risk both live.

The cash math is the quiet constraint

Operating cash use was $6.34 million in the quarter; nine-month adjusted EBITDA loss was $15.6 million. Against that, the October IPO netted $17.0 million, EXIM released $2.1 million of restricted cash and pushed the liquidity covenant to 2028, and cash stood at $19.3 million on October 31 — roughly three quarters of runway at the current burn, before any gross-margin recovery. The argon recycling system arriving in Q1 2027 and the targeted 77% cut in argon cost are therefore not just margin icing; they are the cheapest capital the company has. Capacity is not the scarce resource here. Time and cash are. For a market that spent the last ninety days marking down anything tied to AI data-center buildouts, Amaero offers an oddly clean counter-position: submarine components, hypersonics, sovereign powder supply, a Tennessee plant already 90% paid for at $52.2 million of invested capital. The story is credible. The quarter is not yet proof of it — and the fourth atomizer arriving into slack capacity will be the test of whether management's operating-leverage thesis is a forecast or a hope.